CompletedInterventionalPhase 2Last updated Jul 15, 2026

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Palbociclib Combine With Endocrine Therapy and Anti-HER2 Therapy in HR Positive and HER2 Positive Advanced Breast Cancer

Overview

ClinicalTrials.gov ID: NCT05969184
Lead Sponsor: Peking University Cancer Hospital & InstituteOTHER
Brief Summary: This study is to find out that if HER-2 positive and HR positive patients could benefit from trastuzumab and pertuzumab combined with palbociclib and endocrine therapy.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Dec 12, 2021Actual
Primary Completion Date: Apr 25, 2026Actual
Completion Date: Jun 25, 2026Actual

Study Record Dates

First Submitted: Dec 14, 2022
First Submitted that Met QC Criteria: Jul 31, 2023
First Posted: Aug 1, 2023Actual
Last Update Submitted that Met QC Criteria: Jul 13, 2026
Last Update Posted: Jul 15, 2026Actual
Last Verified: Jun 2025

NCT03969121Completed

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

NCT02947685Active, not recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

NCT05343117Unknown status

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

NCT07299890Not yet recruiting

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

NCT02530424Completed

"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "

NCT05577442Unknown status

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer